查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1560331

先进治疗市场报告：2030 年趋势、预测与竞争分析

Advanced Therapy Medicinal Products Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日期: | 出版商: Lucintel | 英文 150 Pages | 商品交期: 3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

先进治疗药物的趋势与预测

到2030年，全球先进治疗药物（ATMP）市场预计将达到199亿美元，2024年至2030年的复合年增长率为13.5%。该市场的关键驱动因素是医疗保健支出的增加、慢性病盛行率的增加、有利的法规环境和政府支持的扩大。全球先进治疗药物市场前景广阔，细胞治疗、CAR-T治疗、基因治疗和组织工程产品市场充满机会。

在这个市场中，组织工程产品将继续成为最大的细分市场，因为它们在创伤治疗和再生医学应用中的应用越来越广泛。

由于癌症、心血管疾病和神经退化性疾病等慢性疾病的高盛行率，北美将继续成为最大的市场。

先进治疗药物市场新趋势

有几个关键趋势正在重塑先进医学格局并导致先进治疗市场的发展。其中包括技术、监管和研究重点的变化，这些变化将影响 ATMP 的开发和采用。

  • 人工智慧和机器学习的整合：利用人工智慧 (AI) 和机器学习进行 ATMP 开发和优化的趋势日益明显。人工智慧被用来分析复杂的生物资料，识别潜在的治疗靶点，并简化开发过程。这种整合将确保治疗的准确性并缩短新药的上市时间。
  • 个人化医疗的扩展：个人化医疗正在主导 ATMP 市场。基因组学和生物技术的进步使得为具有不同基因的人开发治疗方法成为可能。最大限度地减少副作用和改善治疗是开发有效治疗方法整个计划的重点。
  • 推动再生医学的创新：组织工程、干细胞疗法和其他再生医学如今正在迅速发展。从退化性疾病到创伤，这些进步为解决医疗问题提供了新方法。再生医学领域正在创造机会并扩大 ATMP 的范围。
  • 增加监管支援：目前世界各地对 ATMP 开发和核准的监管支援正在增加。简单的认证方法和最新的指南有助于将新治疗方法更快地推向市场。这表明世界不仅有兴趣改善患者获得更好治疗方法的机会，而且也有兴趣鼓励发明。

ATMP 市场的新趋势正在再形成先进治疗领域，包括人工智慧整合、再生医学创新、个人化医疗和监管支援。最终，这些趋势将推动该细分市场的成长，因为它们会改善 ATMP 的开发、疗效并改善患者的治疗结果。

新兴市场开拓的最新趋势

最近的趋势正在影响先进治疗市场的发展。这种变化是由基因和细胞疗法的创新、技术突破以及监管进步所推动的。因此，这些进步不仅增加了治疗方法选择，也提高了价格和效率，塑造了全球市场趋势。

  • 新型基因疗法的核准：最近新型基因疗法的核准对 ATMP 市场产生了重大影响。这些疗法为治疗曾经被认为无法治癒的遗传性疾病提供了新的可能性。例如，Zolgensma用于脊髓性肌肉萎缩症的基因疗法的核准表明基因疗法可以针对罕见和复杂的疾病，并且其他类似的突破性努力将随之而来，人们认为这将继续下去。
  • CAR-T细胞疗法的进展：随着新治疗方法的引入和现有治疗方法适应症的扩大，嵌合体抗原受体T细胞（CAR-T）疗法取得了重大进展。例如，Kymriah 和 Yescarta 是其中的一些治疗方法，它们对某些癌症表现出良好的疗效，从而扩大了治疗选择，并导致了我所做的 ATMP 市场的肿瘤学领域的增长。
  • 扩大法规结构：法律规范的製定和完善促进了 ATMP 的推进和核准。监管机构正在透过创建快速核准流程并提供更清晰的指示来简化从研究到市场的路径。这些进步对于支持先进疗法的创新和商业化是必要的。
  • 个人化医疗的整合： ATMP 中个人化医疗方法的整合正在迅速进展。次世代定序等技术越来越多地实现基于个人基因图谱的客製化治疗。这种客製化提高了治疗效果，反映了个人化医疗的成长趋势。

ATMP 市场正在受到近期趋势的显着影响，例如基因和细胞疗法的进步、管理该领域的法规的改进以及投资的增加。这些事件透过扩大患者可用的治疗选择、改善患者的治疗结果并为 ATMP 的进一步创新和进步奠定基础，推动市场成长。

先进治疗市场的策略性成长机会

先进治疗市场在各种应用中都有几个策略性成长机会。技术的进步、患者需求的增加以及支持性的法规环境提供了这些机会。透过开拓这些细分市场可以促进市场扩张，从而带来未来突破性的治疗方法。

  • 扩大癌症治疗：ATMP 市场的肿瘤领域具有显着的成长前景。 CAR-T 创新和其他以细胞为基础的治疗方法为无反应性癌症疾病提供了新的治疗选择。将这些治疗方法扩展到更广泛的患者和不同的癌症代表着一个重大的成长机会。
  • 罕见疾病治疗发展：罕见疾病和罕见疾病治疗方法的开发是主要的成长领域。针对特定遗传疾病的基因疗法和其他先进疗法正变得越来越普遍。除了解决以前未满足的医疗需求之外，这种方法还吸引了大量投资和监管支援。
  • 再生医学的进展：再生医学领域透过干细胞疗法和组织工程正在迅速发展。在修復和替换受损组织和器官方面还有很大的成长空间。但发明可以为心臟病、脊椎损伤和神经退化疾病提供新的治疗方法。
  • 数位医疗技术的融合：ATMP 和数位医疗技术的结合可以成为成长的机会。这些数位工具可以透过监测患者、收集资料和优化治疗来提高这些治疗方法的有效性。这增加了增强的解决方案，例如个人化治疗方法以及改进的患者管理。

ATMP 市场的策略性成长机会包括癌症治疗、罕见疾病治疗、再生医学、数位健康整合以及向新兴市场扩张的进步。这些有可能显着成长市场。这些机会促进了创新治疗方法的发展并改善了全球患者照护。

先进治疗药物市场推广因素及挑战

先进治疗市场的开拓和成长受到多种市场驱动因素和挑战的影响。这些分别包括技术进步、监管支援和患者需求的增加。然而，该领域最大的挑战仍然存在，包括成本上升、严格的法规和复杂的製造流程。因此，了解这些问题对于成功驾驭市场非常重要。

推动先进治疗市场的因素包括：

1.技术进步：基因编辑、细胞治疗和再生医学是ATMP市场的主要驱动力。在疑难杂症的治疗方面，包括CRISPR基因编辑工具、CAR-T细胞在内的新技术代表医学的新成就。结果，他们的影响范围扩大了，先进的治疗方法本身也变得更有效。

2. 监管支持：ATMP 的成长和核准得益于支持性的法规环境。加快的监管核准流程已经到位，更明确的指导方针提供了从研究到商业化的清晰路径。值得注意的是，创新和市场扩张依赖此类监管支援。

3.患者需求增加：市场扩张的驱动力是对先进疗法的认识和需求不断增长。治疗方案需要个人化、有效，并且主要针对寻求医疗服务的复杂罕见疾病患者。这种需求继续推动 ATMP 领域进行进一步的研究和开发。

先进治疗药物市场问题如下。

1.高成本：开发和製造ATMP的挑战之一是其高成本。这些治疗方法复杂且研究和製造成本高昂，限制了治疗的获得并抑制了市场成长。为了更广泛的采用和永续性，解决成本问题非常重要。

2. 监理障碍：透过 ATMP法律规范既复杂又耗时。儘管有法律体制，但严格的要求使公司很难获得核准。成功的市场进入要求这些公司密切管理所有监管流程。

3.製造复杂性：ATMP的製造过程涉及复杂的程序和品管步骤。保持一致的产品品质和可扩展性可能很困难，并且会导致製造效率低下和成本高昂。克服这些挑战对于满足市场需求同时确保产品可靠性至关重要。

虽然技术进步、不断增长的患者需求和监管支援是影响先进治疗药物 (ATMPS) 市场的驱动因素和挑战，但其他挑战包括高成本、监管障碍和製造复杂性等。这些驱动因素需要与这些障碍同时解决，从而促进该领域的更多创新，扩大市场成长率，并更有效地利用先进医疗设施的专利保护。

按细分市场分類的先进疗法

该调查按产品和地区对全球先进治疗药物进行了预测。

先进治疗药物市场的国家前景

由于基因治疗、细胞治疗和再生医学的市场开拓，全球先进治疗药物市场正在发生重大变化。这些变化正在定义一种注重个人化治疗、更好的表现和更广泛的覆盖范围的护理形式。美国、中国、德国、印度和日本是透过各种方式为先进治疗市场的成长和转型做出贡献的关键国家。

  • 美国：美国在 ATMP 方面取得了重大进展，重点是基因和细胞疗法的接受和商业化。 FDA 最近批准了多种针对备受瞩目的遗传疾病和癌症的治疗方法，导致该领域出现更多发明和成长。新的指南设置和资助计划也正在推动这一领域的研究。
  • 中国：随着大力投资开发 CRISPR 基因编辑技术和细胞治疗方法临床试验的进展，中国正迅速转向 ATMP。因此，透过政策变革和中国政府的资助，先进治疗方法的开发速度更快，使该公司成为全球市场的主要参与企业之一。
  • 德国：德国透过发展再生医学和干细胞研究，巩固了其在先进治疗市场的地位。例如，细胞和基因治疗研究专门中心的建立正在促进科学家之间的创造力和合作。此外，德国的监管基础设施正在发生变化，以便能够将 ATMP 安全地融入临床实践。
  • 印度：在印度，ATMP 市场正在扩大，越来越注重开发廉价且易于取得的基因和细胞疗法。此外，新的生物技术进步和政府支持政策正在推动市场扩张。此外，印度公司透过国际合作推动研究并将新治疗方法推向市场，为全球 ATMP 开发做出贡献。
  • 日本：日本在再生医学领域处于领先地位，在干细胞治疗和基因编辑方面取得了重大进展。日本政府透过投资界促进 ATMP核准并促进创新。此外，日本目前致力于将先进的治疗方法直接引入主流医疗服务，从而改善患者的选择。

常问问题

Q.1 先进治疗药物的市场规模有多大？

答：到 2030 年，全球先进治疗市场预计将达到 199 亿美元。

Q.2 先进治疗药物市场的成长预测如何？

答：2024年至2030年，全球先进治疗市场预计将以13.5%的复合年增长率成长。

Q.3 影响先进治疗市场成长的关键驱动因素有哪些？

答：这个市场的主要驱动力是医疗保健支出的增加、慢性病盛行率的上升、有利的法规环境和政府支持的增加。

Q4.市场的主要细分市场是什么？

答：先进治疗市场的未来前景广阔，细胞治疗、CAR-T治疗、基因治疗和组织工程产品市场都有机会。

Q5.市场上主要企业有哪些？

答：主要的先进疗法公司有：

  • Spark Therapeutics
  • Bluebird Bio
  • Novartis
  • Uniqure
  • Celgene Corporation
  • Gilead Lifesciences
  • Kolon Tissue gene
  • JCR Pharmaceuticals
  • Medipost
  • Vericel Corporation

Q6.未来五年预计哪个地区的市场规模最大？

答：由于癌症、心血管疾病和神经退化性疾病等慢性病的高盛行率，北美仍将是最大的细分市场。

Q7. 可以客製化报告吗？

答：是的，Lucintel 列出了 10% 的客製化服务，无需额外费用。

目录

第一章执行摘要

第二章全球先进治疗药物市场：市场动态

  • 简介、背景、分类
  • 供应链
  • 产业驱动因素与挑战

第三章 2018-2030年市场趋势及预测分析

  • 宏观经济趋势（2018-2023）与预测（2024-2030）
  • 全球先进治疗药物市场趋势（2018-2023）与预测（2024-2030）
  • 按产品分類的全球先进治疗市场
    • 细胞疗法
    • CAR-T疗法
    • 基因治疗
    • 组织工程产品

第四章 2018-2030年区域市场趋势及预测分析

  • 按地区分類的全球先进疗法市场
  • 北美先进治疗药物市场
  • 欧洲先进治疗药物市场
  • 亚太先进治疗市场
  • 其他地区先进治疗药物市场

第五章 竞争分析

  • 产品系列分析
  • 营运整合
  • 波特五力分析

第六章 成长机会与策略分析

  • 成长机会分析
    • 按产品分類的全球先进治疗市场成长机会
    • 按地区分類的全球先进治疗市场成长机会
  • 全球先进治疗市场的新兴趋势
  • 战略分析
    • 新产品开发
    • 扩大全球先进治疗药物市场产能
    • 全球先进治疗市场的合併、收购和合资企业
    • 认证和许可

第七章主要企业概况

  • Spark Therapeutics
  • Bluebird Bio
  • Novartis
  • UniQure
  • Celgene Corporation
  • Gilead Lifesciences
  • Kolon TissueGene
  • JCR Pharmaceuticals
  • MEDIPOST
  • Vericel Corporation
简介目录

Advanced Therapy Medicinal Products Trends and Forecast

The future of the global advanced therapy medicinal products market looks promising with opportunities in the cell therapy, CAR-T therapy, gene therapy, and tissue engineered product markets. The global advanced therapy medicinal products market is expected to reach an estimated $19.9 billion by 2030 with a CAGR of 13.5% from 2024 to 2030. The major drivers for this market are rising healthcare spending, increasing prevalence of chronic diseases, and favorable regulatory environment and growing government support.

Within this market, tissue engineered product will remain the largest segment due to its increasing adoption in wound healing and regenerative medicine applications.

North America will remain the largest segment due to high prevalence of chronic diseases, such as cancer, cardiovascular diseases, and neurodegenerative diseases.

Emerging Trends in the Advanced Therapy Medicinal Products Market

There are several key trends that are reshaping the landscape of advanced medical treatments, leading to an evolution of the advanced therapy medicinal products (ATMPs) market. These include changes in technology, regulations and research priorities, which shape the development and adoption of ATMPs.

  • Integration of AI and Machine Learning: It is a growing trend to use artificial intelligence (AI) and machine learning for developing and optimizing ATMPs. This is where AI is used to analyze complex biological data, identify potential targets for therapy, streamline development processes among others. The integration ensures accuracy in treatment while speeding up time-to-market for new drugs.
  • Personalised Medicine Expansion: Personalised medicine is dominating the ATMP market. Genomics and biotechnology are becoming more advanced making it possible to create therapies for people with different genes. The entire plan is focused on ensuring that treatment is improved with minimal side effects in order to develop effective therapeutic agents.
  • Innovations Driving Regenerative Medicine: Tissue engineering, stem cell therapy and other facets of regenerative medicine are rapidly advancing today. From degenerative diseases to traumatic injuries, these advancements offer new approaches for dealing with medical conditions. The area of regenerative medicine has created opportunities, which have in turn increased the scope of ATMPs.
  • Rise in Regulatory Backing: There is now greater support for developing and approving ATMPs by regulatory bodies around the world. Easy approval methods and updated guidelines assist in speeding up the introduction of new therapies into the market. This signifies a worldwide interest in encouraging inventions as well as improving patient access to superior treatments.

The field of advanced therapies is being reshaped by emerging trends in the ATMP market such as AI integration; regenerative medicine innovations; personalized medicine and regulatory support among others. Ultimately these trends are improving development, effectiveness of ATMPs that leads to better patient outcomes thus driving growth in this sector.

Recent Developments in the Advanced Therapy Medicinal Products Market

Recently, there have been significant developments that are influencing the evolution of the advanced therapy medicinal products (ATMPs) market. This transformation is driven by innovations in gene and cell therapies as well as technological breakthroughs and regulatory advancements. Thus, these strides not only increase therapeutic options but also improve their affordability and efficiency, thus shaping the global markets trends.

  • Approval of Novel Gene Therapies: Recent approvals of novel gene therapies have had a marked effect on the ATMP market. These treatments offer new possibilities for treating genetic conditions once deemed incurable. For instance, where gene therapy has been approved for Zolgensma for spinal muscular atrophy, this suggests that gene therapy can target rare or complex disorders and other similar groundbreaking initiatives will follow suit.
  • Advances in CAR-T Cell Therapy: Chimeric Antigen Receptor T-cell (CAR-T) therapy has experienced notable advances with newer therapies being introduced and existing ones expanded indications. For example, Kymriah and Yescarta are some of such treatments which have shown great efficacy against certain forms of cancer thus improving treatment options hence growth in the oncology segment of ATMP market.
  • Expansion of Regulatory Frameworks: A development and refinement of regulatory frameworks has allowed the progress and approval of ATMPs. Regulatory agencies are creating fast-track approval procedures and providing clearer instructions, thus simplifying the path from research to market. These developments are necessary for supporting innovation and commercialization of advanced therapies.
  • Integration of Personalized Medicine: The integration of personalized medicine approaches in ATMPs is on a fast track. Technology such as next-generation sequencing is now enabling tailored therapies that are based on one's own genetic profile. This customization improves treatment efficacy, reflecting the increasing trend towards personalized healthcare.

The ATMP market is being shaped significantly by recent developments that include advancements in gene and cell therapies, improvements in regulations governing the sector, and increased investment. These occurrences are expanding the treatment options available to patients, improving patient outcomes and fueling market growth thereby setting a platform for more innovation and advancement of ATMPs.

Strategic Growth Opportunities for Advanced Therapy Medicinal Products Market

There are several strategic growth opportunities across different applications within advanced therapy medicinal products (ATMPs) market. Technological advancements, increasing patient needs and supporting regulatory environments provide these opportunities. Market expansion can be driven through exploring these areas that can lead to future ground breaking treatments.

  • Expansion of Oncology Treatments: The oncology segment of the ATMP market offers significant growth prospects. CAR-T innovations and other cell-based therapies have presented new treatment alternatives for non-responsive cancer ailments. Expanding these therapies among wide range of patients as well as diverse cancers represents one large opportunity for growth.
  • Rare Disease Therapies Development: Developing therapies for rare and orphan diseases is a major area of growth. Gene therapies for specific genetic conditions are becoming popular and other advanced treatments. Apart from addressing medical needs that have not been met, this approach also attracts huge investments as well as regulatory support.
  • Advances in Regenerative Medicine: The field of regenerative medicine is rapidly evolving through stem cell treatments and tissue engineering. A lot of room for growth exists in repairing or replacing damaged tissues or organs. Inventions can however deliver new remedies to heart ailments-spine injuries-neurodegenerative states.
  • Merging Digital Health Technologies: The use of ATMPs together with digital health technologies could be an opportunity for growth. By employing these digital tools in the monitoring patients, collecting data and optimizing treatment methods, it is possible to enhance the effectiveness of these therapeutic options. This will add enhanced solutions like personalized treatments methods along with improved patient management into this combination.

Strategic growth opportunities in the ATMP market include advancements in oncology treatments, rare disease therapies, regenerative medicine, digital health integration and expansion into emerging markets. These can propel the market to significant growth. Through these opportunities, development of innovative therapies and improving patient care globally is possible.

Advanced Therapy Medicinal Products Market Driver and Challenges

The development and growth of the advanced therapy medicinal products (ATMPs) market are influenced by several drivers and challenges. These include technological advances, regulatory support as well as increased patients' demand respectively. On one hand; increased costs high regulations and complex manufacturing processes remain top challenges regarding this area. To successfully navigate the market therefore, it is critical to understand these issues.

The factors responsible for driving the advanced therapy medicinal products market include:

1. Technological Advancements: Gene editing, cell therapy and regenerative medicine have acted as a major driver for ATMP market. In terms of treatment of incurable diseases novel technologies including CRISPR gene editing tool or CAR-T cells usage represent new achievements in medical sciences. Consequently, their reach has been broadened enhancing their efficiency for advanced therapies themselves.

2. Regulatory Support: The growth and approval of ATMPs are being facilitated by supportive regulatory environments. Accelerated approval processes are being implemented by regulatory agencies as well as clearer guidelines that provide a clear path from research to commercialization. It is important to note that the innovation and market expansion depend on this regulation support.

3. Increasing Patient Demand: Market expansion is driven by increasing awareness and demand for advanced therapies. Treatment options need to be personalized, effective and tailored mainly for patients with complex rare diseases who seek healthcare services. This demand continues to push the ATMP sector towards further research & development.

Challenges in the advanced therapy medicinal products market are:

1. High Costs: One of the challenges in the development and production of ATMPs is their high cost. These therapies are intricate and costly to research and produce, thus limiting access to them and impeding market growth. For broader adoption as well as sustainability it is important to address cost concerns.

2. Regulatory Hurdles: Navigating through ATMP regulatory frameworks can be complex as well as time-consuming. This has been despite establishment of supportive legal frameworks; however, stringent requirements have made it hard for these companies in obtaining approvals. Successful entry into the market necessitates a close management of all regulatory processes by these firms.

3. Manufacturing Complexities: The manufacturing process for ATMPs involves intricate procedures and quality control steps. Maintaining consistent product quality and scalability can prove challenging leading to inefficiency in production and high costs. Overcoming these challenges is important if we want to meet the demands of the market while ensuring that our products remain reliable.

Technological advancements, increasing patient demand, regulatory support among others are some of the drivers influencing advanced therapy medicinal products (ATMPS) market while other challenges include high costs, regulatory hurdles, manufacturing complexities among others. Drivers like this require being tackled alongside such obstacles so that more innovation can take place within this field thereby expanding its market growth rate whereas making sure patents receive better actuation towards advanced medical care facilities.

List of Advanced Therapy Medicinal Products Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies advanced therapy medicinal products companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the advanced therapy medicinal products companies profiled in this report include-

  • Spark Therapeutics
  • Bluebird Bio
  • Novartis
  • Uniqure
  • Celgene Corporation
  • Gilead Lifesciences
  • Kolon Tissue gene
  • JCR Pharmaceuticals
  • Medipost
  • Vericel Corporation

Advanced Therapy Medicinal Products by Segment

The study includes a forecast for the global advanced therapy medicinal products by product and region.

Advanced Therapy Medicinal Products Market by Product [Analysis by Value from 2018 to 2030]:

  • Cell Therapy
  • CAR-T Therapy
  • Gene Therapy
  • Tissue Engineered Product

Advanced Therapy Medicinal Products Market by Region [Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

Country Wise Outlook for the Advanced Therapy Medicinal Products Market

Advanced therapy medicinal products market is changing significantly across the globe as a result of developments in gene and cell therapies, as well as regenerative medicine. These transformations are determining the shape of medical treatments that concentrate on individualized treatments, better performance, and wider reachability. United States, China, Germany, India and Japan are the leading countries in this regard who have contributed differently to grow and change the advanced therapy medicinal products market.

  • United States: In America, there have been significant advancements in ATMPs with emphasis on acceptance and commercialization of genes as well as cell therapies. FDA has recently certified a number of high-profile genetic disorder and cancer treatments resulting to more inventions and growth in the sector. New guidelines setting up and funding initiatives are facilitating researches in this area too.
  • China: With considerable investments made towards CRISPR gene editing technology development alongside progressing clinical trials for cellular based therapies, China is quickly making headways into ATMPs. Thus advanced therapies have been developed more quickly both through policy changes by Chinese government as well as funding from it thereby transforming it into one of key players within global market.
  • Germany: Germany has strengthened its position in the market for Advanced Therapy Medicinal Products (ATMPs) by developing regenerative medicine and stem cell research. For example, the establishment of specialized centers for cell and gene therapy research is promoting creativity and collaboration among the scientists. Moreover, Germany's regulatory infrastructure is changing to allow safe integration of ATMPs into clinical practice.
  • India: In India, the ATMP market is expanding with increasing focus on developing affordable and accessible gene and cell therapies. In addition, emerging biotechnological advancements as well as supportive government policies are pushing for expansion. Furthermore, Indian companies collaborate internationally so as to advance research and bring new therapies to market thereby contributing to global ATMP developments.
  • Japan: Japan is leading in regenerative medicine with notable progress in stem cell therapies and gene editing. The Japanese government has made it easy to approve ATMPs thus encouraging innovation through investment communities. Besides that Japan is now focusing on bringing advanced therapies directly into mainstream healthcare services hence improving choices for patients.

Features of the Global Advanced Therapy Medicinal Products Market

Market Size Estimates: Advanced therapy medicinal products market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Advanced therapy medicinal products size by product and region in terms of value ($B).

Regional Analysis: Advanced therapy medicinal products market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different products and regions for the mucopolysaccharidosis treatment market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the advanced therapy medicinal products market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

FAQ

Q.1 What is the advanced therapy medicinal products market size?

Answer: The global advanced therapy medicinal products market is expected to reach an estimated $19.9 billion by 2030.

Q.2 What is the growth forecast for advanced therapy medicinal products market?

Answer: The global advanced therapy medicinal products market is expected to grow with a CAGR of 13.5% from 2024 to 2030.

Q.3 What are the major drivers influencing the growth of the advanced therapy medicinal products market?

Answer: The major drivers for this market are rising healthcare spending, increasing prevalence of chronic diseases and favorable regulatory environment and growing government support.

Q4. What are the major segments for advanced therapy medicinal products market?

Answer: The future of the advanced therapy medicinal products market looks promising with opportunities in the cell therapy, CAR-T therapy, gene therapy, and tissue engineered product markets.

Q5. Who are the key advanced therapy medicinal products market companies?

Answer: Some of the key advanced therapy medicinal products companies are as follows:

  • Spark Therapeutics
  • Bluebird Bio
  • Novartis
  • Uniqure
  • Celgene Corporation
  • Gilead Lifesciences
  • Kolon Tissue gene
  • JCR Pharmaceuticals
  • Medipost
  • Vericel Corporation

Q6. In advanced therapy medicinal products market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest segment due to high prevalence of chronic diseases, such as cancer, cardiovascular diseases, and neurodegenerative diseases.

Q.7 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the advanced therapy medicinal products market by product (cell therapy, CAR-T therapy, gene therapy, and tissue engineered product), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?
  • Market Report

Table of Contents

1. Executive Summary

2. Global Advanced Therapy Medicinal Products Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Advanced Therapy Medicinal Products Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Advanced Therapy Medicinal Products Market by Product
    • 3.3.1: Cell Therapy
    • 3.3.2: CAR-T Therapy
    • 3.3.3: Gene Therapy
    • 3.3.4: Tissue Engineered Product

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Advanced Therapy Medicinal Products Market by Region
  • 4.2: North American Advanced Therapy Medicinal Products Market
    • 4.2.1: North American Advanced Therapy Medicinal Products Market by Product: Cell Therapy, CAR-T Therapy, Gene Therapy, and Tissue Engineered Product
  • 4.3: European Advanced Therapy Medicinal Products Market
    • 4.3.1: European Advanced Therapy Medicinal Products Market by Product: Cell Therapy, CAR-T Therapy, Gene Therapy, and Tissue Engineered Product
  • 4.4: APAC Advanced Therapy Medicinal Products Market
    • 4.4.1: APAC Advanced Therapy Medicinal Products Market by Product: Cell Therapy, CAR-T Therapy, Gene Therapy, and Tissue Engineered Product
  • 4.5: ROW Advanced Therapy Medicinal Products Market
    • 4.5.1: ROW Advanced Therapy Medicinal Products Market by Product: Cell Therapy, CAR-T Therapy, Gene Therapy, and Tissue Engineered Product

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Advanced Therapy Medicinal Products Market by Product
    • 6.1.2: Growth Opportunities for the Global Advanced Therapy Medicinal Products Market by Region
  • 6.2: Emerging Trends in the Global Advanced Therapy Medicinal Products Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Advanced Therapy Medicinal Products Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Advanced Therapy Medicinal Products Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: Spark Therapeutics
  • 7.2: Bluebird Bio
  • 7.3: Novartis
  • 7.4: UniQure
  • 7.5: Celgene Corporation
  • 7.6: Gilead Lifesciences
  • 7.7: Kolon TissueGene
  • 7.8: JCR Pharmaceuticals
  • 7.9: MEDIPOST
  • 7.10: Vericel Corporation